ClinicalTrials.gg
RecruitingNCT06752772Updated Oct 2, 2025

WeArable teChnology daTa driVen digitAl healTh cOachINg (ACTIVATION)- A Mixed-methods Study

An interventional study of Smart watch and Dashboard with nudging system in Elevated Blood Pressure, Hypertension and Overweight/Obesity, sponsored by Alexandra Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Alexandra Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,700
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Hypertension with a site in Singapore — 16 open to participants now, 20 under way, 3 of them phase 3. Hypertension · Singapore.

Planned enrollment
7th of 44
1,700 · median 170
Started
2024
with 2 others
No phase
24 of 56
9 open now
Primary completion
2025-11
later than 5 of 19 live
Registered
45th of 56
by date
Lead sponsor
2 of 56
Alexandra Hospital

Among the 56 studies in Hypertension with a site in Singapore, this one is the 7th largest by planned enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2024, is one of 24 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 45th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

16 of the 56 studies in Hypertension with a site in Singapore are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Hypertension with a site in Singapore, or all of them as a file.
02

Study summary

Public health priorities have shifted towards disease prevention, emphasising health promotion and lifestyle interventions to reduce disease burden. Despite global efforts, the prevalence of chronic diseases remains high, with lifestyle factors such as alcohol consumption, diet, smoking, obesity, and sedentary behaviour playing significant roles. In Singapore, suboptimal lifestyle behaviours are common, contributing to a high incidence of chronic conditions. Metabolic syndrome (MetS), linked to obesity, poses a growing societal burden due to its association with cardiovascular risks. Disparities exist in the delivery of lifestyle interventions among healthcare providers (HCPs), with many patients receiving inadequate guidance. Digital health coaching, incorporating wearable technology, offers promising solutions to bridge these gaps, providing personalised, real-time support and feedback to improve lifestyle behaviours and prevent disease progression. Challenges such as time constraints, lack of feedback, and limited support can be addressed through remote monitoring and tailored interventions, making scalable population-level interventions feasible.

03

Conditions studied

  • Elevated Blood Pressure
  • Hypertension
  • Overweight/Obesity
  • Type 2 Diabetes Mellitus (T2DM)
  • Hyperlipidemia
  • Prediabetes

Keywords

  • Digital Health Intervention
  • Health Coaching
  • Personalisation
  • Nudging
  • Wearables
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 21-75 years old
  • Patients who are at risk of any of the following:

    1. Elevated blood pressure
    2. Overweight (>=23kg/m2)
    3. Pre-diabetes, OR
  • Patients who have one or more of the following (HOLD) conditions:

    1. Hypertension
    2. Obesity (BMI>=27.5kg/m2)
    3. HyperLipidemia
    4. Type 2 Diabetes Mellitus
  • Patients who own a smartphone
  • Patients who are willing to wear a smartwatch during the intervention period.

Exclusion criteria

Exclusion Criteria:

  • Patients who have a medical condition that prevented participation in physical activity
  • Patients who have current diagnosis or history of eating disorder, depression
  • Patients who are currently pregnant or planning to become pregnant in the next 6 months
  • Patients who are currently participating in a weight loss programme (commercial, medically supervised, or research study)
  • Patients who are on weight loss medications (over-the-counter or prescription)
  • Patients who are not mentally-, physically- or technologically-capable
  • Patients who is unable to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,700 participants (estimated)

Study arms

  • Active comparator
    Group 1: Smart Watch only

    Participants will need to undergo HbA1c and lipid blood tests to determine if they have pre-diabetes, diabetes, or hyperlipidemia if they lack recent blood results (within 3 months prior to enrolment) for blood glucose and/or lipid levels. Participants assigned to Group 1 are required to fill out questionnaires covering aspects such as sociodemographic, lifestyle, medical condition, healthcare utilisation, quality of life, self-efficacy, distress and personality measures at study baseline, as well as at 3-, 6-, 9-, and 12-months following study enrolment. Participants will be issued a Fitbit Smartwatch and are required to wear the smart watch for at least 8 hours a day for a total duration of 6 months. Participants are encouraged to continue their normal daily activities while wearing the smart watch.

    Device: Smart watch

  • Active comparator
    Group 2: Smart watch + dashboard with nudging system

    Participants will need to undergo HbA1c and lipid blood tests to determine if they have pre-diabetes, diabetes, or hyperlipidemia if they lack recent blood results (within 3 months prior to enrolment) for blood glucose and/or lipid levels. Participants assigned to Group 2 are required to fill out questionnaires covering aspects such as sociodemographic, lifestyle, medical condition, healthcare utilisation, quality of life, self-efficacy, distress and personality measures at study baseline, as well as at 3-, 6-, 9-, and 12-months following study enrolment. Participants will be issued a Fitbit Smartwatch and are required to wear the smart watch for at least 8 hours a day for a total duration of 6 months. Participants are encouraged to continue their normal daily activities while wearing the smart watch.

    Device: Smart watch · Behavioral: Dashboard with nudging system

  • Experimental
    Group 3: Smart watch + dashboard with nudging system + Digital Health Coach (DHC)

    Participants will need to undergo HbA1c and lipid blood tests to determine if they have pre-diabetes, diabetes, or hyperlipidemia if they lack recent blood results (within 3 months prior to enrolment) for blood glucose and/or lipid levels. Participants assigned to Group 3 are required to fill out questionnaires covering aspects such as sociodemographic, lifestyle, medical condition, healthcare utilisation, quality of life, self-efficacy, distress and personality measures at study baseline, as well as at 3-, 6-, 9-, and 12-months following study enrolment. Participants will be issued a Fitbit Smartwatch and are required to wear the smart watch for at least 8 hours a day for a total duration of 6 months. Participants will be assigned to a DHC and the DHC will be providing you with remote health coaching assistance for a duration of 6 months. Participants are encouraged continue their normal daily activities while wearing the smart watch.

    Device: Smart watch · Behavioral: Dashboard with nudging system · Device: Digital Health Coach (DHC)

Interventions

  • DeviceSmart watch

    Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.

  • BehavioralDashboard with nudging system

    Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.

  • DeviceDigital Health Coach (DHC)

    Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.

06

What researchers measure

Primary outcomes

  1. Changes in physical activity level

    Change in physical activity level will be measured using the International Physical Activity Questionnaire Short Form (IPAQ-SF) scale at baseline, 6- and 12-month post study enrolment. Higher score indicates a higher level of physical activity.

    Time frame: Baseline, 6- and 12-month post study enrolment

Secondary outcomes

  1. Engagement and sustainability

    Duration of wearables wear time will be assessed throughout the study.

    Time frame: Baseline, 3- , 6-, 9-, and 12-month post study enrolment

  2. Acceptability of the study

    In-depth qualitative interviews will be conducted to assess acceptability of the study.

    Time frame: 6-, 9- and 12-month post study enrolment

  3. Satisfaction towards the intervention provided

    Satisfaction will be measured through Client Satisfaction Questionnaire (CSQ-8) for Group 3 participants. CSQ-8 uses a 4-point Likert scale, with higher score indicating greater satisfaction.

    Time frame: 6-month post study enrolment

  4. Lifestyle changes (Diet)

    Changes in diet intake will be measured through Healthy Eating Assessment (HEA) scale. Health Benefit score is calculated, and a higher score indicates that participants are in a possible healthier benefit zone.

    Time frame: Baseline, 6-, and 12-month post enrolment

  5. Lifestyle changes (Smoking Cessation)

    Changes in smoking behaviour will be measured through Cigarette Dependence Scale (CDS-12). Higher score indicates a greater level of possible cigarette dependence.

    Time frame: Baseline, 6-, and 12-month post enrolment

  6. Lifestyle changes (Alcohol Cessation)

    Changes in alcohol consumption will be measured through Alcohol User Disorders Identification Test (AUDIT). Higher score indicates a greater level of possible alcohol dependence.

    Time frame: Baseline, 6-, and 12-month post enrolment

  7. Self-efficacy

    Self-efficacy will be measured through General Self-Efficacy (GSE) Scale. Higher score indicates a greater level of self-efficacy.

    Time frame: Baseline, 6-, and 12-month post enrolment

  8. Quality of Life

    Changes in quality of life will be measured through EuroQol 5-Dimension 5-Level Health Questionnaire (EQ-5D-5L). Index scores closer to 1 indicates a better possible health state; a higher EQ-VAS score closer to 100 indicates a better possible health state.

    Time frame: Baseline, 6-, and 12-month post enrolment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2025, 15 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 15 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Dec 31, 2024
StartActual
Aug 6, 2024
Primary completionEst.
Nov 2025
CompletionEst.
Feb 2026
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06752772
Lead sponsor
Alexandra Hospital
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Aug 6, 2024
Primary completion
Nov 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Oct 2, 2025

Study contacts

Elya Elya
Contact
ah_activation@nuhs.edu.sg
96505306
Jacqueline Lau
Contact
ah_activation@nuhs.edu.sg
96505306

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion